Over the past two decades, Ranbaxy has established a robust distribution network in Ukraine and is today catering to 25 regions.
Ranbaxy Laboratories Limited (Ranbaxy), India’s largest pharmaceutical company, is celebrating its 20th anniversary in Ukraine. Establishing its operation in the Ukraine market in 1993, Ranbaxy is today the No. 1 player in the target market segment with key brands such as Cifran (Ciprofloxacin), Zanocin (Ofloxacin) and Ketanov (Ketorolac) and a market share of 10.3% (Morion, MAT Q3, 2013).
Over the past two decades, Ranbaxy has established a robust distribution network in Ukraine and is today catering to 25 regions. The company markets branded generic and over-the-counter (OTC) products and is well known for its innovative marketing capabilities with a number of brands in leadership position.
The therapeutic segments cover anti-infectives, gastrointestinal, cardiovascular, non-steroidal anti-inflammatory drugs (NSAID), urology, OTC and Anti-retrovirals (ARVs). Some of the leading brands in Ukraine include Ketanov, Pylobact NEO, Candesar range, Cifran, Synerpen and Faringosept. The company has in the past, bagged the prestigious Panacea Award for Ketanov, Cifran and Faringosept.
Arun Sawhney, CEO & Managing Director, Ranbaxy said, “Ranbaxy has been providing high quality, affordable generic medicines to the citizens of Ukraine for the last two decades, thereby supporting the Government to bring down healthcare costs. We remain committed to the Ukraine market and its people and will continue to operate from our paradigm of Quality and Patients First”.
Alok Batra, MD, Ranbaxy Ukraine said, “The Ukraine pharmaceutical market is driven by generics and there is immense potential for growth. We have strong professional team with established brands in the market and most of brands rank amongst the top three in their respective segments. In the coming years, we will be introducing more products in the CVS, GI, OTC, Anti-Infectives etc segments to benefit doctors and patients in Ukraine.”
The Ukraine pharmaceutical retail market is estimated at around US $ 3.7 billion (Morion, MAT Q3, 2013) and is growing at a CAGR (MAT 3Q 2011- MAT 3Q 2013) of around 15%.
Over the past two decades, Ranbaxy has established a robust distribution network in Ukraine and is today catering to 25 regions. The company markets branded generic and over-the-counter (OTC) products and is well known for its innovative marketing capabilities with a number of brands in leadership position.
The therapeutic segments cover anti-infectives, gastrointestinal, cardiovascular, non-steroidal anti-inflammatory drugs (NSAID), urology, OTC and Anti-retrovirals (ARVs). Some of the leading brands in Ukraine include Ketanov, Pylobact NEO, Candesar range, Cifran, Synerpen and Faringosept. The company has in the past, bagged the prestigious Panacea Award for Ketanov, Cifran and Faringosept.
Arun Sawhney, CEO & Managing Director, Ranbaxy said, “Ranbaxy has been providing high quality, affordable generic medicines to the citizens of Ukraine for the last two decades, thereby supporting the Government to bring down healthcare costs. We remain committed to the Ukraine market and its people and will continue to operate from our paradigm of Quality and Patients First”.
Alok Batra, MD, Ranbaxy Ukraine said, “The Ukraine pharmaceutical market is driven by generics and there is immense potential for growth. We have strong professional team with established brands in the market and most of brands rank amongst the top three in their respective segments. In the coming years, we will be introducing more products in the CVS, GI, OTC, Anti-Infectives etc segments to benefit doctors and patients in Ukraine.”
The Ukraine pharmaceutical retail market is estimated at around US $ 3.7 billion (Morion, MAT Q3, 2013) and is growing at a CAGR (MAT 3Q 2011- MAT 3Q 2013) of around 15%.
No comments:
Post a Comment